Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 171 for “"Irinotecan"”.
-
The Combination of Carboxylesterase-Expressing Oncolytic Vaccinia Virus and Irinotecan
… combines oncolytic Vaccinia virus (VV) with irinotecan (CPT-11) for the treatment of cancer. VV can infect, replicate in and destroy cancer cells, yet leave healthy cells relatively unaffected. CPT-11 is a chemotherapeutic of which ~5% is converted to the more active chemotherapeutic SN-38 by …
-
Effects of Inflammation and Soy Isoflavones on Irinotecan Pharmacokinetics and Toxicity
… as the liver or lungs through the bloodstream. Irinotecan is an intravenous (i.v.) infusion chemotherapy drug that was approved by FDA in 1996 and it is a topoisomerase I inhibitor indicated for first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic …
-
A study linking toll-like receptors and irinotecan-induced gastrointestinal mucositis.
… cancer treatment. The efficacy and safe use of irinotecan (a topoisomerase I inhibitor chemotherapeutic drug) is compromised because of GIM. Severe GIM often necessitates dose reduction or treatment discontinuation thus compromising patient survival. In rat studies, irinotecan has been shown to …
-
Molecular Mechanisms of Irinotecan Induced Fatty Liver Disease and Drug-Drug Interaction
… without compromising their efficacy. Irinotecan is a very potent neoadjuvant chemotherapy for colorectal liver metastases but its treatment is associated with non-alcoholic fatty liver disease (NAFLD or FLD) that increases risk for post-operative morbidity and mortality. Drug-induced …
-
Pharmacometric modeling of anti-cancer agents: application to gemcitabine, PQIP and irinotecan.
We performed pharmacometric modeling of irinotecan, PQIP and gemcitabine. Irinotecan is a DNA topoisomerase-I inhibitor used in colorectal and brain tumors. One of our aims was to show that that cranial radiation, delivered during irinotecan administration, can enhance uptake in to cerebral-spinal …
-
Development of irinotecan hydrochloride loaded PLGA nanoparticles for the treatment of glioblastoma
… drug delivery to the brain. In this study, Irinotecan Hydrochloride (IRN)-loaded poly(lactide-co- glycolide) (PLGA) NPs and IRN and Pitavastatin (PTV) co-loaded PLGA NPs were developed to improve their delivery to the brain and increase their efficacy as a treatment for GBM. The IRN-loaded …
-
Development Of Specific Natural Bacterial Beta-Glucuronidase Inhibitors For Reducing Irinotecan-Associated Diarrhea
Irinotecan is a derived compound from the plant alkaloid camptothecin (CPT). It specifically inhibits eukaryotic DNA enzyme topoisomerase I. Irinotecan was approved by the FDA as the second-line therapy for metastatic colon or rectal cancer in 1996. However, one of its leading side effects is …
-
Neuroprotective and Anti-Cancer Efficacy of APX3330 Given in Combination with Irinotecan and Oxaliplatin
… or with radiation. Oxaliplatin (OXL) and Irinotecan (IRI) are the most common chemotherapy medications used in the clinical setting for CRC treatment. Regardless of the success rate of reducing disease progression and increasing survival, these drugs cause acute and chronic toxicities that …
-
Correlating Irinotecan and Capecitabine Treatment for Colorectal Cancer to Gene Expression, Polymorphisms, and Clinical Outcomes
… preoperative treatment with capecitabine and irinotecan (CPT-11) combination followed by chemoradiation with capecitabine and finally surgery to improve response and decrease local recurrence. Irinotecan and Capecitabine are both prodrugs activated in vivo to SN-38 and 5-FU, respectively. …
-
The role of matrix metalloproteinases and their inhibitors in irinotecan-induced oral mucositis: an animal model.
Background: Chemotherapy-induced oral mucositis is defined as damage of oral mucosa caused by unwanted detrimental effects of the cytotoxic chemotherapy. Oral mucositis presents as widespread painful ulcerations and erythematous eruptions and occurs in between 40-100% of all patients undergoing …
-
Human Carboxylesterase 2 Splice Variants: Expression, Activity, and Role in the Metabolism of Irinotecan and Capecitabine
… carboxylesterase genes CES1, CES2, and CES3. Irinotecan (CPT-11) and capecitabine are important chemotherapeutic prodrugs that are used for the treatment of colorectal cancer. Of the three CES isoenzymes, CES2 has the highest catalytic efficiency for irinotecan activation. There is large …
-
Untersuchungen zum morphologischen Ablauf und zur Regulation der mitotischen Katastrophe in Kolonkarzinomzellen nach Behandlung mit Irinotecan
Der Topoisomerase-I-Inhibitor Irinotecan (CPT-11) sowie sein aktiver Metabolit SN-38 lösen in p53wt-Kolorektalkarzinomzelllinien einen lang anhaltenden Zellzyklusarrest und in p53mut-Zellen einen transienten Arrest aus, gefolgt von Apoptose. Da die meisten Kolonkarzinome im p53-Gen eine Mutation …
-
DEVELOPMENT OF LIPOSOME FORMULATIONS CO-ENCAPSULATING TOPOISOMERASE INHIBITORS IRINOTECAN AND DOXORUBICIN FOR THE TREATMENT OF OVARIAN CANCER
… that the combination of doxorubicin and irinotecan may be synergistic when administered together in the treatment of platinum-resistant ovarian carcinoma. With the well-known ability to reduce adverse side effects of the encapsulated drug and deliver the drugs to the tumor site, it is …
-
Toll-like receptor 4-dependent barrier dysfunction and its impact on irinotecan-induced gut toxicity and pain
The format of my thesis is as follows: a general introduction, a literature review, two research chapters, a second literature reviews, three research chapters, a general discussion and references. During my candidature, I made significant effort to publish my research findings. Each research …
-
Pharmakokinetische und pharmakogenetische Studien zur Optimierung und Individualisierung der Therapie maligner Erkrankungen am Beispiel von Idarubicin und Irinotecan
… an diese Ziele zu verfolgen. Für die Irinotecan-Therapie, die als First-line-Therapie zur Behandlung des metastasierenden kolorektalen Karzinoms eingesetzt wird, stellt eine Dosisindividualisierung aufgrund von genetischen Unterschieden einen vielversprechenden Ansatz dar. In der …
-
The Role of Multi-Drug Resistance Associated Protein 4 and P-glycoprotein in Resistance of Neuroblastoma to Topotecan and Irinotecan
… The camptothecin analogs topotecan and irinotecan have been identified as successful cytotoxic agents. For topotecan, pharmacokinetically guided dosing to achieve a systemic exposure associated with preclinical anti-tumor activity in neuroblastoma xenograft models is feasible and has …
Page 1 of 9